PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28244642-7	2017	Further analysis using cultured urothelial cells revealed that acrolein, the major metabolite of CYP, caused protein oxidation, p38 activation, and urothelial injury.	Acrolein	63-71	mitogen-activated protein kinase 14	Mus musculus	128-131	
28244642-8	2017	These effects of acrolein were reproduced by TRPV4 agonists and significantly prevented by antioxidant NAC, p38 inhibitor SB203580, TRPV4 antagonist RN-1734, and CBX.	Acrolein	17-25	mitogen-activated protein kinase 14	Mus musculus	108-111	
19661247-11	2009	In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor.	Acrolein	10-18	mitogen-activated protein kinase 14	Mus musculus	259-265	
19631294-0	2009	p38 MAPK and MMP-9 cooperatively regulate mucus overproduction in mice exposed to acrolein fog.	Acrolein	82-90	mitogen-activated protein kinase 14	Mus musculus	0-8	
19631294-2	2009	METHODS: Mice were exposed to 4.0 ppm of acrolein for 21 days with daily intraperitoneal injection of SB203580, a specific inhibitor of p38 MAPK.	Acrolein	41-49	mitogen-activated protein kinase 14	Mus musculus	136-144	
19631294-8	2009	Acrolein-increased phosphorylation of p38 MAPK was significantly reduced by SB203580.	Acrolein	0-8	mitogen-activated protein kinase 14	Mus musculus	38-46